NCT06660732View on ClinicalTrials.gov

Rilonacept in Subjects With Cardiac Sarcoidosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions
Cardiac Sarcoidosis
Interventions
DRUG

Rilonacept

320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.

Trial Locations (2)

21205

RECRUITING

Johns Hopkins University, Baltimore

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Mayo Clinic

OTHER

NCT06660732 - Rilonacept in Subjects With Cardiac Sarcoidosis | Biotech Hunter | Biotech Hunter